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Severe hypophosphatemia can cause generalized muscle
weakness, paralysis of the respiratory muscles, myocardial
dysfunction, reduced peripheral vascular resistance, and
encephalopathy. Here we conducted a prospective study to
determine the incidence of hypophosphatemia in 47 children
on continuous renal replacement therapy and to evaluate the
efficacy and safety of adding phosphate to the replacement
and dialysate solutions of 38 pediatric patients. During
continuous renal replacement therapy, 68% of patients were
found to have hypophosphatemia, significantly more than
the 12% of patients at the beginning of therapy. There was
no higher incidence of hypophosphatemia among patients
requiring insulin, diuretics, parenteral nutrition, or high doses
of vasoactive drugs. In the children to whom phosphate was
not added to replacement and dialysate solutions, 85%
presented with an incidence of hypophosphatemia and 36%
required intravenous phosphate replacement, rates
significantly higher than in those patients where phosphate
was added to the solutions. Phosphate supplementation did
not cause any instability of the mixtures or other
complications. We show here that the incidence of
hypophosphatemia in children on continuous renal
replacement therapy is very high. Further, we show that the
addition of phosphate to replacement and dialysate solutions
is safe and that it reduces the incidence of
hypophosphatemia and the need for intravenous phosphate
treatment.
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Severe hypophosphatemia in critically ill patients can cause
generalized muscle weakness and even paralysis of the
respiratory muscles, myocardial dysfunction, reduced per-
ipheral vascular resistance, and encephalopathy. It is therefore
necessary to correct its levels by the intravenous administra-
tion of phosphate.1,2
Continuous renal replacement therapy (CRRT) achieves a
high clearance of low molecular weight solutes such as
phosphate.3 In adults, hypophosphatemia is very common
during CRRT due to the high efficacy of these techniques and
the fact that the solutions usually used for replacement and
dialysis do not contain phosphate. The incidence of
hypophosphatemia is increased by the use of high ultrafiltra-
tion flows4 and during prolonged treatment.
The addition of phosphate to the replacement and
dialysate solutions could help to reduce the incidence of
hypophosphatemia. There is only one study in critically ill
adults undergoing CRRT in which phosphate was added to
the replacement and dialysate solutions;3 no studies have
been published on this subject in pediatric patients.
The objectives of our study were to analyze the incidence
of hypophosphatemia in critically ill children treated with
CRRT, and its associated risk factors, and to evaluate the
safety and efficacy of the addition of phosphate to the
replacement solutions.
RESULTS
The study population was formed of 85 patients. The mean
age was 4.9 years (range, 6 days to 22 years, with only one
patient over 18 years of age) and the mean weight was 18.9 kg
(range, 2.5–85 kg). All patients underwent CRRT; in 47
patients (33 continuous venovenous hemodiafiltration and
14 continuous venovenous hemofiltration), the replacement
and dialysate solutions did not contain phosphate (group 1,
no intervention); and in 38 patients, the solutions contained
phosphate supplements (group 2). In group 2, phosphate was
only added to the replacement solution in 27 patients (8 of
these because they did not undergo dialysis), only to the
dialysate in 2 patients, and to both solutions in 9 patients.
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The distribution of patients according to phosphate supple-
mentation is shown in Table 1.
The diagnoses of the 85 patients are shown in Table 2. The
most common diagnoses were the cardiopathies: 66% of
these patients were in the postoperative period of cardiac
surgery, including six patients after heart transplant, and the
remainder presented congestive cardiac failure due to various
etiologies. The indications for starting CRRT are shown in
Table 3. The mean ultrafiltration flow was 62.2 ml/h (5.6 ml/
kg/h), the mean dialysate flow was 562.3 ml/h (26.9 ml/kg/h),
and the mean (s.d.) filtration rate (ultrafiltration plus
dialysis) was 35.5 (24.4) ml/kg/h.
Before starting CRRT, 10 patients (12%) presented
hypophosphatemia; 6 of these patients were younger than
12 months. Seven patients (8%) presented hyperphosphate-
mia (phosphate 47 mg/100 ml). During CRRT, 58 patients
(68%) presented hypophosphatemia, and this was severe in
33 (38.8%).
Other risk factors for hypophosphatemia were analyzed. A
continuous infusion of insulin was used at some time during
CRRT in 17% of patients; these patients did not present a
higher incidence of hypophosphatemia. Parenteral nutrition
was administered to 30.5% of patients and these patients
presented a slightly higher incidence of hypophosphatemia
(76%) than the children receiving enteral nutrition (65%),
although the difference was not significant. Hypophosphate-
mia was detected in 63% of patients receiving diuretics
and in 72% of those not receiving these drugs; this
difference was not significant. The inotropic index
(dopamineþ dobutamineþ (epinephrine 100)þ (norepi-
nephrine 100)þ (isoproterenol 100)þ (milrinone 15)
in mg/kg/min) was greater than 10 in 61 patients. There was
no significant difference in the incidence of hypopho-
sphatemia between these patients (64%) and the children
with an inotropic index less than 10 (79%). The incidence of
hypophosphatemia was significantly higher in children under
72 months of age than in older patients during the course of
the study (Table 4). The duration of admission to the
pediatric intensive care unit before starting CRRT was not
associated with a higher incidence of hypophosphatemia.
Patients with a higher filtration rate during CRRT
presented a higher incidence of hypophosphatemia. The
mean filtration rate (ultrafiltrationþ dialysis/kg) in patients
with hypophosphatemia was 37.7 (28.5) ml/kg/h and in those
without hypophosphatemia was 30.5 (21.9) ml/kg/h
(P¼ 0.290). The incidence of hypophosphatemia was higher
in children with a filtration rate greater than 40 ml/kg/h
(76.7%) than in the other patients (63.6%), although the
difference was not statistically significant (P¼ 0.236).
The incidence of hypophosphatemia in the patients who
did not receive phosphate in the replacement and dialysate
solutions was 85% (40 of 47 patients), compared with 55%
(18 of 38 patients) in the children who did receive phosphate
supplements (Po0.001). The incidence of severe hypo-
phosphatemia was also significantly higher in the patients
who did not receive phosphate supplements in the dialysis or
replacement solutions (57%) than in those who did receive
these supplements (16%) (P¼ 0.013). Intravenous phosphate
treatment was required in 21 cases, 17 (36.1%) of the patients
in group 1 and 4 (10.5%) in group 2 (Po0.013).
There was a fall in the phosphate levels during treatment
in both groups (Figure 1). Before starting treatment, seven
patients presented phosphate levels greater than 7 mg/100 ml,
and the phosphate levels fell in all these patients during
CRRT; three of these patients were in the group that received
phosphate supplements in the solutions, and these supple-
ments could be started 24 h after the initiation of CRRT.
There were no cases of hyperphosphatemia that required
withdrawal of the phosphate supplements from the solutions.
Hypocalcemia (total calciumo8 mg/100 ml) was detected
in 12.7% of patients before starting CRRT; this fell to 5%
during treatment. There was no significant difference in the
incidence of hypocalcemia between the patients with and
without phosphate supplements (10 and 12%, respectively).
Hypercalcemia (total calcium 412 mg/100 dl) was detected
in one patient at the beginning of therapy and in two patients
during CRRT.
Table 1 | Distribution of the patients according to phosphate
supplementation
Phosphate in the solutions Number of patients CVVHDF CVVHF
No (group 1) 47 33 14
Yes (group 2) 38 30 8
In the replacement solution 27 19 8
In the dialysis solution 2 2 0
In both solutions 9 9 0
CVVHDF, continuous venovenous hemodiafiltration; CVVHF, continuous venove-
nous hemofiltration.
Table 2 | Diagnoses of the patients
Diagnosis Frequency Percentage
Cardiopathy, postoperative period
of cardiac surgery
45 52.9
Sepsis 15 17.6
Chronic renal failure 6 7
Postoperative period of abdominal surgery 4 4.7
Congenital metabolic disease 5 6
Hemolytic-uremic syndrome 3 3.5
Tumor lysis syndrome 2 2.3
Others 5 6
Total 85 100
Table 3 | Indications for renal replacement therapy
Indication Frequency Percentage
Acute renal failure 35 41.2
Hypervolemia 19 22.4
Acute renal failure and hypervolemia 25 29.4
Tumor lysis syndrome 2 2.4
Others 4 4.7
Total 85 100
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Hypomagnesemia (magnesium o1.5 mg/100 ml) before
starting CRRT was found in 4% of patients and, at the end of
treatment, in 6%. There were no cases of hypomagnesemia in
the patients with solutions supplemented with phosphate. At
the start of CRRT, three patients presented magnesium levels
43 mg/100 ml. Hypermagnesemia was detected in five
patients (7.2%) during treatment, three in the group without
phosphate supplements and two in the group with these
supplements; this difference was not significant.
DISCUSSION
CRRT causes hypophosphatemia, particularly if it is required
for a prolonged period.3–6 The incidence is higher with CRRT
than with intermittent techniques such as hemodialysis.5 This
is due to the fact that although hemodialysis is initially more
effective in clearing phosphate, it is only performed for a few
hours, whereas the continuous techniques, on being used
throughout the day, remove a larger quantity of this solute.1,7
The frequency of phosphate disturbances in critically ill
patients is high, although the figure varies considerably
depending on the study, between 8.8 and 80%.1,8 In our
study, the incidence of hypophosphatemia starting CRRT was
12% in the overall group of 85 children. The incidence of
hyperphosphatemia (8%) was much lower than that found in
adults, a population in which 65–80% of patients present
hyperphosphatemia before starting CRRT.5,6 This is probably
due to the early indication for CRRT in our center in patients
with hypervolemia refractory to diuretics or with oliguric
renal failure, before electrolyte disturbances develop.
During CRRT, 68% of the patients presented hypopho-
sphatemia, and this was severe in 38%. These percentages are
much higher than those reported in adults, probably because
the baseline phosphate levels before CRRT were normal in
the majority of patients. In a study by Morimatsu et al.,6
hyperphosphatemia was present in 62% of adult patients
before starting hemodiafiltration and in 73% before hemofil-
tration. A significant fall in the phosphate levels occurred
with both techniques. Hypophosphatemia developed in 10%
of patients on hemodiafiltration and in 14% of patients on
hemofiltration (P¼ 0.22) within 48 h after starting the
filtration technique, but hyperphosphatemia persisted in
30% of patients.
In our study, we have also evaluated other risk factors
associated with the onset of hypophosphatemia. Children
under 6 years of age presented a higher risk of hypopho-
sphatemia than older children. We did not find a higher
percentage of hypophosphatemia in patients requiring
insulin, diuretics, or high doses of vasoactive drugs, or in
those who received parenteral nutrition or had a longer stay
in the pediatric intensive care unit. Some authors recom-
mend the use of high ultrafiltration flow rates,4 although
there is insufficient evidence that this improves survival.9 In
our study, the use of high-volume ultrafiltration slightly
increased the incidence of hypophosphatemia, although this
was not significant.
The second objective of our study was to evaluate the
safety and efficacy of the addition of phosphate to the
replacement and dialysate solutions in order to decrease
hypophosphatemia. There is only one previous report on this
subject, published by Troyanov et al.;3 this study involved
adults and phosphate was added to the replacement and
dialysate solutions (1.2 mmol/l). The solutions were of a
similar composition to those used in our center and
contained the same quantity of calcium (1.75 mmol/l).
Troyanov observed that there was no fall in the calcium or
phosphate concentrations in the bags after 5 h, nor did any
precipitate develop in these bags after 48 h; filtration of the
solution through cellulose membranes with a pore size of
0.22 mm did not capture any visible particles. Subsequently,
that author treated 20 adult patients for 5 days, observing
that the phosphate levels remained within the normal range
and that there were no adverse effects of the treatment, except
for hyperphosphatemia in one patient to whom an oral
laxative containing 180 mmol of phosphate was inadvertently
administered.3
In our study we used monosodium phosphate as this is
the preparation available in our hospital and also because it
Table 4 | Percentage of patients with hypophosphatemia, classified according to age
Percentage with hypophosphatemia o6 years 6–16 years 416 years Total P-value
24 h 47.9 20 0 35.8 0.008
48 h 56.8 25.9 0 43.2 0.02
72 h 56.2 26.1 0 42.1 0.03
At the end of treatment 58.6 13.6 0 37 0.001
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Figure 1 | Changes in the phosphate levels during the first
72 h of treatment. Comparison between patients with and
without phosphorus supplements in the replacement and dialysis
solutions. P indicates phosphorus.
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enabled us to regulate the administration of potassium
independently from that of the phosphate; if hypokalemia
was detected, supplements of potassium chloride were added
to the solutions. The incidence of hypophosphatemia was
significantly lower in the children in whom phosphate
supplements were added to the solutions than in those in
whom the supplements were not added, and the incidence of
severe hypophosphatemia was also significantly lower. Fewer
patients in the group with phosphate supplements in the
replacement and dialysate solutions required the administra-
tion of intravenous phosphate. However, the phosphate levels
did fall in both groups during treatment, and the incidence of
hypophosphatemia in the group with phosphate supplements
was still high; the possibility for increasing these supplements
therefore needs to be investigated. In our study we cannot
compare the efficacy of phosphate supplementation in
replacement solution, dialysis solution or both solutions.
However, we think that is better to add phosphate in both
solution (replacement and dialysis) to avoid the pass of
phosphate from blood to the dialysis solution and the
dilution of blood with a replacement solution without
phosphate.
The third objective of the study was to evaluate the safety
of the administration of phosphate and the incidence of
complications derived from this intervention. Apart from the
study by Troyanov,3 commented above, there are publications
that state that the addition of phosphate to the dialysate
solutions does not cause complications in cases of methanol
or ethylene glycol intoxication, in which very severe
hypophosphatemia occurs due to the need to use hemo-
dialysis for many hours.10,11
The possibility that the mixture of calcium and phosphate
will precipitate into particles that are at the limit of detection
of the human eye and could lead to pulmonary micro-
embolisms is a cause for concern with the mixtures of
parenteral nutrition. However, the concentration of these
ions in parenteral nutrition solutions is higher than that of
the replacement and dialysate solutions.
In our study, we observed no problems of stability of the
mixture, and precipitation did not occur. In the supplemen-
ted solutions, in the worst case of calcium phosphate salt
formation (precipitation of all the calcium with the
phosphate), this would give concentrations of 0.06–0.13 g/l
below the threshold for precipitation as the salt is soluble up
to concentrations of 0.2–0.3 g/l.3 If precipitation occurred,
patients could theoretically develop hypocalcemia. However,
in our study, the incidence of hypocalcemia before starting
therapy was 12.7% and, during therapy, this fell to 5%.
Adding phosphate to the solutions did not increase the
percentage of patients with hypocalcemia. Nor were there any
cases of hyperphosphatemia that required withdrawal of the
phosphate from the hemofiltration solutions, and there were
no disturbances of magnesium levels.
There are certain limitations to our study. Although the
protocol and solutions for CRRT were the same in all
patients, the fact that this was an observational study
performed over a long period of time, initially without
intervention and subsequently with intervention, means that
bias due to the patients’ illnesses and to other treatments that
could affect phosphate levels and the phosphate concentra-
tion in parenteral and enteral nutrition cannot be completely
excluded, although this would not alter the basic results of
the study.
In conclusion, there is a high incidence of hypopho-
sphatemia in children treated with continuous venovenous
filtration techniques. The addition of 0.8 ml/l of mono-
sodium phosphate to the replacement and dialysate solutions
is safe, does not produce adverse effects, reduces the
incidence of hypophosphatemia, and reduces the need for
intravenous phosphate replacement. Phosphate should there-
fore be added routinely to the replacement and dialysate
solutions of all children undergoing CRRT, starting at the
initiation of treatment, except in those children who present
severe hyperphosphatemia.
MATERIALS AND METHODS
A prospective study was performed including all patients admitted
to a pediatric intensive care unit and who underwent CRRT by
means of continuous venovenous hemofiltration or continuous
venovenous hemodiafiltration between November 2001 and August
2007. The study was approved by the Hospital Ethics Committee.
The more frequent indications for CRRT were acute renal failure
and/or hypervolemia. The criteria for starting CRRT depended of
the clinical situation of each patient. We try to treat early acute renal
failure and hypervolemia (positive fluid balance in spite of
furosemide infusion up to 1 mg/kg/h plus bolus), although
creatinine and urea values had not very high to avoid excessive
edema, electrolytes alterations and worsening of multiorganic
failure.
This was an observational study with no intervention between
2001 and 2005 and with intervention between 2005 and 2007,
adding 0.8 ml of monosodium phosphate (H2PO4, 1 mmol/ml and
Na 1 mmol/ml) to each liter of the replacement and dialysate
solutions.
Patients with hyperphosphatemia (phosphate 47 mg/100 ml) or
at risk of a tumor lysis syndrome were excluded from phosphate
supplementation.
Epidemiological data (age, weight, diagnosis) and the indication
for CRRT and its characteristics (mean replacement flow, mean
dialysate flow) were collected in all cases. The phosphate, calcium,
and magnesium levels were recorded before CRRT, at 24, 48, and
72 h after starting therapy, and at the end of therapy. Other risk
factors for hypophosphatemia, such as extracorporeal surgery,
sepsis, parenteral nutrition, administration of insulin, diuretics, or
high doses of vasoactive drugs, and the length of stay in the pediatric
intensive care unit, were also recorded. Other data collected
Table 5 | Criteria for hypophosphatemia used in the study
Age
(years)
Moderate hypophosphatemia
(mg/100 ml)
Severe hypophosphatemia
(mg/100 ml)
o6 o4 o3
6–16 o3 o2
416 o2 o1.5
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included the need for intravenous phosphate replacement and the
clinical course of the patients.
Hypophosphatemia was defined according to age, based
on pediatric studies (Table 5).12–15 Adult ranges were used for
children over 16 years of age, considering hypophosphatemia to be
present with a serum phosphate level below 3 mg/100 ml and
moderate hypophosphatemia with phosphate less than
2 mg/100 ml.1,2
A Prisma monitor (Hospal, Gambro, Madrid, Spain) was used to
perform the CRRT in all cases. Filters of 0.04, 0.6, or 0.9 m2 were
used according to the age and weight of the patient. The filter was a
biocompatible synthetic membrane of polyacrylonitrile with a pore
cut-off point of 40 kDa and with a high ultrafiltration coefficient
(Kuf of 16 ml/h/mm Hg for M60 and 22 ml/h/mm Hg for M100).
Replacement was performed prefilter in all cases.
The replacement solution used in all cases was ClearFlex D6
(Bieffe Medital, Grossoto, Italy), which has the following concentra-
tions: Na, 140 mEq/l; HCO3, 40 mEq/l; and Cl, 100 mEq/l. To this
solution we added: 3.25 mEq/l of 10% calcium gluconate, 1.2 mEq/l of
15% magnesium sulfate, 125 mg/100 ml of 50% glucose, and between
0 and 4 mEq/l of 2 M KCl, determined according to the patient’s
requirements.
The dialysis solution used was Dialisan CVVHD (Hospal) which
has the following composition: Na, 140 mmol/l; K, 2 mmol/l;
calcium, 1.75 mmol/l; lactate, 3 mmol/l; glucose, 110 mg/100 ml;
HCO3, 32 mmol/l; and Cl, 111.5 mmol/l. We added 2 M KCl
according to the patient’s potassium levels.
The SPSS statistical package, version 15 (SPSS Inc., Chicago, IL,
USA) was used to perform the statistical study, expressing quantitative
variables as means and standard deviations, and qualitative variables as
percentages. Analysis of normality was performed using the
Kolmogorov–Smirnov test. The w2-test and Fisher’s exact test were
used for the analysis of qualitative variables. Comparison of
quantitative variables between independent groups was performed
using the t-test, and t-test for dependent samples and analysis of
variance were used for repeated measures. The nonparametric tests
used when the distributions of the variables were not normal were the
Mann–Whitney test and Wilcoxon signed rank test.
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